Forum Discussion
Two steps forward, one step back – news on access to CDKs in second line treatment
Hello everyone,
BCNA has an update on access to CDKs as
second line treatment. Pfizer have this week advised BCNA about a new capped access
program for the CDK inhibitor palbociclib (lbrance) wh...
ESMO 2018
Commenting on the findings for ESMO, Dr Carmen Criscitiello, European Institute of Oncology Milan, Italy, said: “These data were much awaited, as the clinical benefit obtained with CDK 4/6 inhibitors was incontestable, but there was the hot question whether the PFS benefit translates into OS benefit. This randomised Phase III trial shows for the first time an improvement in OS with a CDK4/6 inhibitor in the metastatic setting for ER+/HER2- breast cancer.”
https://www.esmo.org/Press-Office/Press-Releases/PALOMA3-breast-cancer-palbociclib-fulvestrant-Cristofanilli
The data is slowly coming in to show what most of us expected clinically - overall improved survival with CDK4/6, numbers stronger in bone only disease.
Commenting on the findings for ESMO, Dr Carmen Criscitiello, European Institute of Oncology Milan, Italy, said: “These data were much awaited, as the clinical benefit obtained with CDK 4/6 inhibitors was incontestable, but there was the hot question whether the PFS benefit translates into OS benefit. This randomised Phase III trial shows for the first time an improvement in OS with a CDK4/6 inhibitor in the metastatic setting for ER+/HER2- breast cancer.”
https://www.esmo.org/Press-Office/Press-Releases/PALOMA3-breast-cancer-palbociclib-fulvestrant-Cristofanilli
The data is slowly coming in to show what most of us expected clinically - overall improved survival with CDK4/6, numbers stronger in bone only disease.